Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 61

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Psoriatic arthropathy

Not yet recruiting

Study on the Effectiveness of Ixekizumab and Methotrexate for Treating Dactylitis in Patients with Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:Azienda Ospedaliera Ordine Mauriziano Di Torino

Study on Premedication with Ketamine or Fentanyl for Patients with Respiratory Distress Syndrome Receiving Surfactant Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Fentanyl Citrate
  • Sponsor:Pohjois-Pohjanmaan hyvinvointialue

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Ospedale San Raffaele S.r.l.

Endocrine ophthalmopathy

Not yet recruiting

Study on the Effects of TOUR006 for Adults with Thyroid Eye Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG2 MONOCLONAL ANTIBODY AGAINST IL-6
  • Sponsor:Tourmaline Bio Inc.

Rheumatoid arthritis

Not yet recruiting

Study on Filgotinib and Triamcinolone for Newly Diagnosed Rheumatoid Arthritis Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:Medisch Spectrum Twente

Type 1 diabetes mellitus

Not yet recruiting

A study evaluating a combination of glucagon and insulin lispro to improve insulin absorption in adults with Type 1 diabetes

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glucagon
  • Sponsor:St. Olavs Hospital HF

Asthma

Not yet recruiting

Study on Adjusting Omalizumab Dosage for Patients with Severe Allergic Asthma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

HIV infection

Not yet recruiting

Study on the Safety and Immune Response of the 9-Valent HPV Vaccine in Women Living with HIV

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:CHU Saint Pierre

Transplant rejection

Not yet recruiting

Study on Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Treating Chronic Kidney Transplant Rejection in Adult Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALLOGENEIC UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS EX VIVO EXPANDED
  • Sponsor:Assistance Publique Hopitaux De Paris

Colitis ulcerative+1

Not yet recruiting

Study on Fecal Microbiota Transplantation with Infliximab and Vedolizumab for Patients with Ulcerative Colitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Varsinais-Suomen hyvinvointialue

HIV infection

Not yet recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.